$61.40
0.20% day before yesterday
Nasdaq, Aug 22, 10:00 pm CET
ISIN
US40131M1099
Symbol
GH

Guardant Health, Inc. Target price 2025 - Analyst rating & recommendation

Guardant Health, Inc. Classifications & Recommendation:

Buy
88%
Hold
9%
Sell
3%

Guardant Health, Inc. Price Target

Target Price $61.20
Price $61.40
Deviation
Number of Estimates 27
27 Analysts have issued a price target Guardant Health, Inc. 2026 . The average Guardant Health, Inc. target price is $61.20. This is lower than the current stock price. The highest price target is , the lowest is .
A rating was issued by 34 analysts: 30 Analysts recommend Guardant Health, Inc. to buy, 3 to hold and 1 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Guardant Health, Inc. stock has an average upside potential 2026 of . Most analysts recommend the Guardant Health, Inc. stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 739.02 911.65
31.04% 23.36%
EBITDA Margin -54.29% -25.10%
41.33% 53.77%
Net Margin -59.05% -43.06%
30.55% 27.08%

30 Analysts have issued a sales forecast Guardant Health, Inc. 2025 . The average Guardant Health, Inc. sales estimate is

$912m
Unlock
. This is
9.99% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$937m 13.00%
Unlock
, the lowest is
$838m 1.09%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $739m 31.04%
2025
$912m 23.36%
Unlock
2026
$1.1b 21.43%
Unlock
2027
$1.4b 23.40%
Unlock
2028
$1.7b 22.04%
Unlock
2029
$1.8b 8.04%
Unlock
2030
$2.6b 46.81%
Unlock
2031
$3.1b 16.83%
Unlock
2032
$3.5b 14.31%
Unlock

26 Analysts have issued an Guardant Health, Inc. EBITDA forecast 2025. The average Guardant Health, Inc. EBITDA estimate is

$-229m
Unlock
. This is
45.39% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-142m 66.08%
Unlock
, the lowest is
$-320m 23.54%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-401m 23.12%
2025
$-229m 42.96%
Unlock
2026
$-155m 32.46%
Unlock
2027
$-89.9m 41.85%
Unlock
2028
$88.0m 197.92%
Unlock
2029
$366m 316.34%
Unlock
2030
$678m 84.95%
Unlock
2031
$886m 30.65%
Unlock
2032
$985m 11.19%
Unlock

EBITDA Margin

2024 -54.29% 41.33%
2025
-25.10% 53.77%
Unlock
2026
-13.96% 44.38%
Unlock
2027
-6.58% 52.87%
Unlock
2028
5.28% 180.24%
Unlock
2029
20.35% 285.42%
Unlock
2030
25.64% 26.00%
Unlock
2031
28.67% 11.82%
Unlock
2032
27.89% 2.72%
Unlock

29 Guardant Health, Inc. Analysts have issued a net profit forecast 2025. The average Guardant Health, Inc. net profit estimate is

$-393m
Unlock
. This is
5.13% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-268m 35.25%
Unlock
, the lowest is
$-422m 2.00%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-436m 8.99%
2025
$-393m 10.03%
Unlock
2026
$-335m 14.71%
Unlock
2027
$-261m 22.11%
Unlock
2028
$23.7m 109.10%
Unlock
2029
$76.3m 221.63%
Unlock
2030
$521m 582.33%
Unlock
2031
$694m 33.25%
Unlock
2032
$787m 13.49%
Unlock

Net Margin

2024 -59.05% 30.55%
2025
-43.06% 27.08%
Unlock
2026
-30.25% 29.75%
Unlock
2027
-19.09% 36.89%
Unlock
2028
1.42% 107.44%
Unlock
2029
4.24% 198.59%
Unlock
2030
19.69% 364.39%
Unlock
2031
22.46% 14.07%
Unlock
2032
22.29% 0.76%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -3.56 -3.15
16.82% 11.52%
P/E negative
EV/Sales 8.93

29 Analysts have issued a Guardant Health, Inc. forecast for earnings per share. The average Guardant Health, Inc. EPS is

$-3.15
Unlock
. This is
5.97% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-2.15 35.82%
Unlock
, the lowest is
$-3.39 1.19%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-3.56 16.82%
2025
$-3.15 11.52%
Unlock
2026
$-2.69 14.60%
Unlock
2027
$-2.10 21.93%
Unlock
2028
$0.19 109.05%
Unlock
2029
$0.61 221.05%
Unlock
2030
$4.18 585.25%
Unlock
2031
$5.57 33.25%
Unlock
2032
$6.32 13.46%
Unlock

P/E ratio

Current -18.33 162.30%
2025
-19.47 6.23%
Unlock
2026
-22.83 17.26%
Unlock
2027
-29.31 28.38%
Unlock
2028
322.23 1,199.39%
Unlock
2029
100.19 68.91%
Unlock
2030
14.68 85.35%
Unlock
2031
11.02 24.93%
Unlock
2032
9.71 11.89%
Unlock

Based on analysts' sales estimates for 2025, the Guardant Health, Inc. stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 9.82 73.50%
2025
8.93 9.04%
Unlock
2026
7.36 17.65%
Unlock
2027
5.96 18.96%
Unlock
2028
4.89 18.06%
Unlock
2029
4.52 7.44%
Unlock
2030
3.08 31.88%
Unlock
2031
2.64 14.41%
Unlock
2032
2.31 12.52%
Unlock

P/S ratio

Current 9.24 72.96%
2025
8.40 9.08%
Unlock
2026
6.92 17.65%
Unlock
2027
5.61 18.96%
Unlock
2028
4.59 18.06%
Unlock
2029
4.25 7.44%
Unlock
2030
2.90 31.88%
Unlock
2031
2.48 14.41%
Unlock
2032
2.17 12.52%
Unlock

Current Guardant Health, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Raymond James
Locked
Locked
Locked Jul 31 2025
Scotiabank
Locked
Locked
Locked Jul 31 2025
Mizuho
Locked
Locked
Locked Jun 13 2025
Piper Sandler
Locked
Locked
Locked May 06 2025
Scotiabank
Locked
Locked
Locked May 05 2025
UBS
Locked
Locked
Locked May 01 2025
Barclays
Locked
Locked
Locked May 01 2025
Analyst Rating Date
Locked
Raymond James:
Locked
Locked
Jul 31 2025
Locked
Scotiabank:
Locked
Locked
Jul 31 2025
Locked
Mizuho:
Locked
Locked
Jun 13 2025
Locked
Piper Sandler:
Locked
Locked
May 06 2025
Locked
Scotiabank:
Locked
Locked
May 05 2025
Locked
UBS:
Locked
Locked
May 01 2025
Locked
Barclays:
Locked
Locked
May 01 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today